This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

< Back

Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line


Cancer and Palliative Care

December 2017

Lenalidomide in combination with bortezomib and dexamethasone is being developed for the treatment of adult patients with MM. While each of these drugs are already approved for treating a range of malignant blood diseases, the combination of the three drugs has shown significant potential particularly for the treatment of newly diagnosed MM. If approved, it will offer an additional treatment option for adult patients whether or not they are eligible or ineligible for bone marrow transplant.


Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Lenalidomide for Multiple Myeloma


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts